Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alvocidib - Tolero Pharmaceuticals

Drug Profile

Alvocidib - Tolero Pharmaceuticals

Alternative Names: Alvocidib hydrochloride; DSP-2033; Flavopiridol; HL-275; HMR 1275; IND 46211; L 868275; MDL-107826A; NSC 649890

Latest Information Update: 19 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer National Cancer Institute (USA); Tolero Pharmaceuticals
  • Class Antineoplastics; Benzopyrans; Flavonoids; Piperidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Germ cell and embryonal neoplasms
  • Phase I/II Myelodysplastic syndromes
  • Preclinical Multiple myeloma
  • No development reported B-cell lymphoma; Chronic lymphocytic leukaemia
  • Discontinued HIV infections; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Reperfusion injury

Most Recent Events

  • 14 Nov 2019 Sumitomo Dainippon Pharma plans to consult with the USFDA for accelerated approval of alvocidib for Myelodysplastic syndromes (Sumitomo Dainippon Pharma November 2019)
  • 28 Oct 2019 Sumitomo Dainippon Pharma announces intention to launch alvocidib for Myelodysplastic syndromes in 2023 (Sumitomo Dainippon Pharma pipeline November 2019)
  • 26 Oct 2019 Pharmacodynamics data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top